The joint pain injections market size has grown rapidly in recent years. It will grow from $6.12 billion in 2025 to $6.89 billion in 2026 at a compound annual growth rate (CAGR) of 12.5%. The growth in the historic period can be attributed to increasing prevalence of arthritis and joint disorders, aging global population, rising demand for minimally invasive pain treatments, growing awareness of regenerative therapies, expansion of orthopedic specialty care.
The joint pain injections market size is expected to see rapid growth in the next few years. It will grow to $10.96 billion in 2030 at a compound annual growth rate (CAGR) of 12.3%. The growth in the forecast period can be attributed to increasing adoption of biologic pain therapies, rising focus on personalized medicine, expansion of sports injury management, growing investments in regenerative medicine, increasing preference for non-opioid pain management. Major trends in the forecast period include increasing adoption of non-surgical pain management therapies, rising use of hyaluronic acid and prp injections, growing demand for personalized pain treatment approaches, expansion of regenerative medicine-based injections, enhanced focus on outpatient pain relief solutions.
The increasing prevalence of arthritis and musculoskeletal disorders is expected to drive growth of the joint pain injections market. Musculoskeletal disorders represent the leading cause of disability globally, with low back pain being the most common cause of impairment across 160 countries. Patients increasingly rely on injections for pain management and treatment of inflammatory conditions. For example, in August 2023, the Institute for Health Metrics and Evaluation (IHME), a U.S.-based independent health research organization, reported that nearly one billion people are projected to be living with osteoarthritis by 2050. Therefore, the growing burden of arthritis and musculoskeletal disorders is fueling demand in the joint pain injections market.
Leading companies in the joint pain injections market are concentrating on developing innovations such as single-injection formulations, which prioritize patient convenience. A single-injection formulation is a type of drug delivery system designed to deliver a specific dose of medication in a single injection, offering sustained therapeutic effects over an extended period without the need for multiple doses. For example, in July 2024, LG Chem Ltd., a chemicals company based in South Korea, introduced Synovian, a new treatment for knee osteoarthritis in China that features a convenient single-injection formulation, making it the first of its kind in the country. The product aims to capture a significant market estimated at around KRW 200 billion (approximately USD 150 million). Developed using proprietary technology, it demonstrates innovation in meeting patient needs, focusing on providing effective relief with minimal administration effort.
In July 2025, Johnson & Johnson MedTech, a U.S.-based provider of medical devices and healthcare solutions, partnered with Pacira BioSciences to expand early-intervention options for knee osteoarthritis. Through this collaboration, both companies aim to increase market adoption of ZILRETTA™, a triamcinolone acetonide extended-release injectable, improve product accessibility, and strengthen presence in the knee osteoarthritis segment. Pacira BioSciences is a U.S.-based specialty pharmaceutical company that develops and commercializes non-opioid pain management and local analgesic products, including intra-articular injections for joint pain.
Major companies operating in the joint pain injections market are Seikagaku Corporation, Anika Therapeutics Inc., Bioventus Inc., Flexion Therapeutics Inc., Ferring Pharmaceuticals Inc., Sanofi S.A., AbbVie Inc., Pfizer Inc., Teva Pharmaceutical Industries Limited, Merck & Co. Inc., Johnson & Johnson, Sun Pharmaceutical Industries Ltd., Zydus Lifesciences Limited, Wockhardt Ltd., Mallinckrodt Pharmaceuticals Ltd., Mylan N.V., Bayer AG, Eli Lilly and Company, Ipsen SA, Takeda Pharmaceutical Company Limited, AstraZeneca plc.
North America was the largest region in the joint pain injections market in 2025. The regions covered in the joint pain injections market report are Asia-Pacific, South East Asia, Western Europe, Eastern Europe, North America, South America, Middle East, Africa. The countries covered in the joint pain injections market report are Australia, Brazil, China, France, Germany, India, Indonesia, Japan, Taiwan, Russia, South Korea, UK, USA, Canada, Italy, Spain.
Tariffs are influencing the joint pain injections market by increasing costs of imported biologics, syringes, processing equipment, and cold-chain packaging materials. Orthopedic clinics and hospitals in North America and Europe are most affected due to reliance on imported injectable formulations, while Asia-Pacific faces cost pressure on biologic production inputs. These tariffs are increasing treatment costs and limiting accessibility for some patients. However, they are also encouraging local biologics manufacturing, regional formulation development, and innovation in cost-efficient injectable therapies.
The joint pain injections market research report is one of a series of new reports that provides joint pain injections market statistics, including joint pain injections industry global market size, regional shares, competitors with a joint pain injections market share, detailed joint pain injections market segments, market trends and opportunities, and any further data you may need to thrive in the joint pain injections industry. This joint pain injections market research report delivers a complete perspective of everything you need, with an in-depth analysis of the current and future scenario of the industry.
Joint pain injections serve to reduce inflammation and discomfort, typically administered directly into the joint to alleviate pain. Joint pain is a common occurrence, particularly among the elderly or individuals with pre-existing medical conditions or disorders. Conditions such as arthritis, characterized by pain and inflammation, often contribute to joint pain. Joint pain injections offer a non-surgical approach to quickly relieve joint pain and inflammation.
The primary types of injections for joint pain include steroid joint injections, hyaluronic acid injections, platelet-rich plasma (PRP) injections, placental tissue matrix (PTM) injections, and various others. Steroid joint injections, also known as corticosteroid injections, are anti-inflammatory medications used to treat joint pain. They are particularly effective in reducing inflammation in individuals with conditions like rheumatoid arthritis and other forms of inflammatory arthritis. Joint pain injections are applied to various types of joints, including the hip joint, knee and ankle joints, shoulder and elbow joints, facet joints of the spine, and others. These injections are commonly distributed through hospital pharmacies, retail pharmacies, and online pharmacies.
The joint pain injections market consists of sales of epidural steroid injections, facet joint injections, viscosupplementation injections, corticosteroid injections and hyaluronic acid injections. Values in this market are ‘factory gate’ values, that is the value of goods sold by the manufacturers or creators of the goods, whether to other entities (including downstream manufacturers, wholesalers, distributors and retailers) or directly to end customers. The value of goods in this market includes related services sold by the creators of the goods.
The market value is defined as the revenues that enterprises gain from the sale of goods and/or services within the specified market and geography through sales, grants, or donations in terms of the currency (in USD unless otherwise specified).
The revenues for a specified geography are consumption values that are revenues generated by organizations in the specified geography within the market, irrespective of where they are produced. It does not include revenues from resales along the supply chain, either further along the supply chain or as part of other products.
This product will be delivered within 1-3 business days.
The joint pain injections market size is expected to see rapid growth in the next few years. It will grow to $10.96 billion in 2030 at a compound annual growth rate (CAGR) of 12.3%. The growth in the forecast period can be attributed to increasing adoption of biologic pain therapies, rising focus on personalized medicine, expansion of sports injury management, growing investments in regenerative medicine, increasing preference for non-opioid pain management. Major trends in the forecast period include increasing adoption of non-surgical pain management therapies, rising use of hyaluronic acid and prp injections, growing demand for personalized pain treatment approaches, expansion of regenerative medicine-based injections, enhanced focus on outpatient pain relief solutions.
The increasing prevalence of arthritis and musculoskeletal disorders is expected to drive growth of the joint pain injections market. Musculoskeletal disorders represent the leading cause of disability globally, with low back pain being the most common cause of impairment across 160 countries. Patients increasingly rely on injections for pain management and treatment of inflammatory conditions. For example, in August 2023, the Institute for Health Metrics and Evaluation (IHME), a U.S.-based independent health research organization, reported that nearly one billion people are projected to be living with osteoarthritis by 2050. Therefore, the growing burden of arthritis and musculoskeletal disorders is fueling demand in the joint pain injections market.
Leading companies in the joint pain injections market are concentrating on developing innovations such as single-injection formulations, which prioritize patient convenience. A single-injection formulation is a type of drug delivery system designed to deliver a specific dose of medication in a single injection, offering sustained therapeutic effects over an extended period without the need for multiple doses. For example, in July 2024, LG Chem Ltd., a chemicals company based in South Korea, introduced Synovian, a new treatment for knee osteoarthritis in China that features a convenient single-injection formulation, making it the first of its kind in the country. The product aims to capture a significant market estimated at around KRW 200 billion (approximately USD 150 million). Developed using proprietary technology, it demonstrates innovation in meeting patient needs, focusing on providing effective relief with minimal administration effort.
In July 2025, Johnson & Johnson MedTech, a U.S.-based provider of medical devices and healthcare solutions, partnered with Pacira BioSciences to expand early-intervention options for knee osteoarthritis. Through this collaboration, both companies aim to increase market adoption of ZILRETTA™, a triamcinolone acetonide extended-release injectable, improve product accessibility, and strengthen presence in the knee osteoarthritis segment. Pacira BioSciences is a U.S.-based specialty pharmaceutical company that develops and commercializes non-opioid pain management and local analgesic products, including intra-articular injections for joint pain.
Major companies operating in the joint pain injections market are Seikagaku Corporation, Anika Therapeutics Inc., Bioventus Inc., Flexion Therapeutics Inc., Ferring Pharmaceuticals Inc., Sanofi S.A., AbbVie Inc., Pfizer Inc., Teva Pharmaceutical Industries Limited, Merck & Co. Inc., Johnson & Johnson, Sun Pharmaceutical Industries Ltd., Zydus Lifesciences Limited, Wockhardt Ltd., Mallinckrodt Pharmaceuticals Ltd., Mylan N.V., Bayer AG, Eli Lilly and Company, Ipsen SA, Takeda Pharmaceutical Company Limited, AstraZeneca plc.
North America was the largest region in the joint pain injections market in 2025. The regions covered in the joint pain injections market report are Asia-Pacific, South East Asia, Western Europe, Eastern Europe, North America, South America, Middle East, Africa. The countries covered in the joint pain injections market report are Australia, Brazil, China, France, Germany, India, Indonesia, Japan, Taiwan, Russia, South Korea, UK, USA, Canada, Italy, Spain.
Tariffs are influencing the joint pain injections market by increasing costs of imported biologics, syringes, processing equipment, and cold-chain packaging materials. Orthopedic clinics and hospitals in North America and Europe are most affected due to reliance on imported injectable formulations, while Asia-Pacific faces cost pressure on biologic production inputs. These tariffs are increasing treatment costs and limiting accessibility for some patients. However, they are also encouraging local biologics manufacturing, regional formulation development, and innovation in cost-efficient injectable therapies.
The joint pain injections market research report is one of a series of new reports that provides joint pain injections market statistics, including joint pain injections industry global market size, regional shares, competitors with a joint pain injections market share, detailed joint pain injections market segments, market trends and opportunities, and any further data you may need to thrive in the joint pain injections industry. This joint pain injections market research report delivers a complete perspective of everything you need, with an in-depth analysis of the current and future scenario of the industry.
Joint pain injections serve to reduce inflammation and discomfort, typically administered directly into the joint to alleviate pain. Joint pain is a common occurrence, particularly among the elderly or individuals with pre-existing medical conditions or disorders. Conditions such as arthritis, characterized by pain and inflammation, often contribute to joint pain. Joint pain injections offer a non-surgical approach to quickly relieve joint pain and inflammation.
The primary types of injections for joint pain include steroid joint injections, hyaluronic acid injections, platelet-rich plasma (PRP) injections, placental tissue matrix (PTM) injections, and various others. Steroid joint injections, also known as corticosteroid injections, are anti-inflammatory medications used to treat joint pain. They are particularly effective in reducing inflammation in individuals with conditions like rheumatoid arthritis and other forms of inflammatory arthritis. Joint pain injections are applied to various types of joints, including the hip joint, knee and ankle joints, shoulder and elbow joints, facet joints of the spine, and others. These injections are commonly distributed through hospital pharmacies, retail pharmacies, and online pharmacies.
The joint pain injections market consists of sales of epidural steroid injections, facet joint injections, viscosupplementation injections, corticosteroid injections and hyaluronic acid injections. Values in this market are ‘factory gate’ values, that is the value of goods sold by the manufacturers or creators of the goods, whether to other entities (including downstream manufacturers, wholesalers, distributors and retailers) or directly to end customers. The value of goods in this market includes related services sold by the creators of the goods.
The market value is defined as the revenues that enterprises gain from the sale of goods and/or services within the specified market and geography through sales, grants, or donations in terms of the currency (in USD unless otherwise specified).
The revenues for a specified geography are consumption values that are revenues generated by organizations in the specified geography within the market, irrespective of where they are produced. It does not include revenues from resales along the supply chain, either further along the supply chain or as part of other products.
This product will be delivered within 1-3 business days.
Table of Contents
1. Executive Summary
2. Joint Pain Injections Market Characteristics
3. Joint Pain Injections Market Supply Chain Analysis
4. Global Joint Pain Injections Market Trends and Strategies
5. Joint Pain Injections Market Analysis of End Use Industries
7. Global Joint Pain Injections Strategic Analysis Framework, Current Market Size, Market Comparisons and Growth Rate Analysis
8. Global Joint Pain Injections Total Addressable Market (TAM) Analysis for the Market
9. Joint Pain Injections Market Segmentation
10. Joint Pain Injections Market Regional and Country Analysis
11. Asia-Pacific Joint Pain Injections Market
12. China Joint Pain Injections Market
13. India Joint Pain Injections Market
14. Japan Joint Pain Injections Market
15. Australia Joint Pain Injections Market
16. Indonesia Joint Pain Injections Market
17. South Korea Joint Pain Injections Market
18. Taiwan Joint Pain Injections Market
19. South East Asia Joint Pain Injections Market
20. Western Europe Joint Pain Injections Market
21. UK Joint Pain Injections Market
22. Germany Joint Pain Injections Market
23. France Joint Pain Injections Market
24. Italy Joint Pain Injections Market
25. Spain Joint Pain Injections Market
26. Eastern Europe Joint Pain Injections Market
27. Russia Joint Pain Injections Market
28. North America Joint Pain Injections Market
29. USA Joint Pain Injections Market
30. Canada Joint Pain Injections Market
31. South America Joint Pain Injections Market
32. Brazil Joint Pain Injections Market
33. Middle East Joint Pain Injections Market
34. Africa Joint Pain Injections Market
36. Joint Pain Injections Market Competitive Landscape and Company Profiles
37. Joint Pain Injections Market Other Major and Innovative Companies
40. Joint Pain Injections Market High Potential Countries, Segments and Strategies
41. Appendix
List of Tables
Executive Summary
Joint Pain Injections Market Global Report 2026 provides strategists, marketers and senior management with the critical information they need to assess the market.This report focuses joint pain injections market which is experiencing strong growth. The report gives a guide to the trends which will be shaping the market over the next ten years and beyond.
Reasons to Purchase:
- Gain a truly global perspective with the most comprehensive report available on this market covering 16 geographies.
- Assess the impact of key macro factors such as geopolitical conflicts, trade policies and tariffs, inflation and interest rate fluctuations, and evolving regulatory landscapes.
- Create regional and country strategies on the basis of local data and analysis.
- Identify growth segments for investment.
- Outperform competitors using forecast data and the drivers and trends shaping the market.
- Understand customers based on end user analysis.
- Benchmark performance against key competitors based on market share, innovation, and brand strength.
- Evaluate the total addressable market (TAM) and market attractiveness scoring to measure market potential.
- Suitable for supporting your internal and external presentations with reliable high-quality data and analysis
- Report will be updated with the latest data and delivered to you along with an Excel data sheet for easy data extraction and analysis.
- All data from the report will also be delivered in an excel dashboard format.
Description
Where is the largest and fastest growing market for joint pain injections? How does the market relate to the overall economy, demography and other similar markets? What forces will shape the market going forward, including technological disruption, regulatory shifts, and changing consumer preferences? The joint pain injections market global report answers all these questions and many more.The report covers market characteristics, size and growth, segmentation, regional and country breakdowns, total addressable market (TAM), market attractiveness score (MAS), competitive landscape, market shares, company scoring matrix, trends and strategies for this market. It traces the market’s historic and forecast market growth by geography.
- The market characteristics section of the report defines and explains the market. This section also examines key products and services offered in the market, evaluates brand-level differentiation, compares product features, and highlights major innovation and product development trends.
- The supply chain analysis section provides an overview of the entire value chain, including key raw materials, resources, and supplier analysis. It also provides a list competitor at each level of the supply chain.
- The updated trends and strategies section analyses the shape of the market as it evolves and highlights emerging technology trends such as digital transformation, automation, sustainability initiatives, and AI-driven innovation. It suggests how companies can leverage these advancements to strengthen their market position and achieve competitive differentiation.
- The regulatory and investment landscape section provides an overview of the key regulatory frameworks, regularity bodies, associations, and government policies influencing the market. It also examines major investment flows, incentives, and funding trends shaping industry growth and innovation.
- The market size section gives the market size ($b) covering both the historic growth of the market, and forecasting its development.
- The forecasts are made after considering the major factors currently impacting the market. These include the technological advancements such as AI and automation, Russia-Ukraine war, trade tariffs (government-imposed import/export duties), elevated inflation and interest rates.
- The total addressable market (TAM) analysis section defines and estimates the market potential compares it with the current market size, and provides strategic insights and growth opportunities based on this evaluation.
- The market attractiveness scoring section evaluates the market based on a quantitative scoring framework that considers growth potential, competitive dynamics, strategic fit, and risk profile. It also provides interpretive insights and strategic implications for decision-makers.
- Market segmentations break down the market into sub markets.
- The regional and country breakdowns section gives an analysis of the market in each geography and the size of the market by geography and compares their historic and forecast growth.
- Expanded geographical coverage includes Taiwan and Southeast Asia, reflecting recent supply chain realignments and manufacturing shifts in the region. This section analyzes how these markets are becoming increasingly important hubs in the global value chain.
- The competitive landscape chapter gives a description of the competitive nature of the market, market shares, and a description of the leading companies. Key financial deals which have shaped the market in recent years are identified.
- The company scoring matrix section evaluates and ranks leading companies based on a multi-parameter framework that includes market share or revenues, product innovation, and brand recognition.
Report Scope
Markets Covered:
1) By Type Of Injection: Steroid Joint Injection; Hyaluronic Acid Injections2) By Joint Type: Hip Joint; Knee And Ankle; Shoulder And Elbow; Facet Joints Of The Spine; Other Joint Types
3) By Distribution channel: Hospital Pharmacies; Retail Pharmacies
Subsegments:
1) By Steroid Joint Injection: Corticosteroid Injections; Combination Steroid Injections2) By Hyaluronic Acid Injections: Single-Dose Hyaluronic Acid Injections; Multi-Dose Hyaluronic Acid Injections
Companies Mentioned: Seikagaku Corporation; Anika Therapeutics Inc.; Bioventus Inc.; Flexion Therapeutics Inc.; Ferring Pharmaceuticals Inc.; Sanofi S.A.; AbbVie Inc.; Pfizer Inc.; Teva Pharmaceutical Industries Limited; Merck & Co. Inc.; Johnson & Johnson; Sun Pharmaceutical Industries Ltd.; Zydus Lifesciences Limited; Wockhardt Ltd.; Mallinckrodt Pharmaceuticals Ltd.; Mylan N.V.; Bayer AG; Eli Lilly and Company; Ipsen SA; Takeda Pharmaceutical Company Limited; AstraZeneca plc
Countries: Australia; Brazil; China; France; Germany; India; Indonesia; Japan; Taiwan; Russia; South Korea; UK; USA; Canada; Italy; Spain
Regions: Asia-Pacific; South East Asia; Western Europe; Eastern Europe; North America; South America; Middle East; Africa
Time Series: Five years historic and ten years forecast.
Data: Ratios of market size and growth to related markets, GDP proportions, expenditure per capita.
Data Segmentation: Country and regional historic and forecast data, market share of competitors, market segments.
Sourcing and Referencing: Data and analysis throughout the report is sourced using end notes.
Delivery Format: Word, PDF or Interactive Report + Excel Dashboard
Added Benefits:
- Bi-Annual Data Update
- Customisation
- Expert Consultant Support
Companies Mentioned
The companies featured in this Joint Pain Injections market report include:- Seikagaku Corporation
- Anika Therapeutics Inc.
- Bioventus Inc.
- Flexion Therapeutics Inc.
- Ferring Pharmaceuticals Inc.
- Sanofi S.A.
- AbbVie Inc.
- Pfizer Inc.
- Teva Pharmaceutical Industries Limited
- Merck & Co. Inc.
- Johnson & Johnson
- Sun Pharmaceutical Industries Ltd.
- Zydus Lifesciences Limited
- Wockhardt Ltd.
- Mallinckrodt Pharmaceuticals Ltd.
- Mylan N.V.
- Bayer AG
- Eli Lilly and Company
- Ipsen SA
- Takeda Pharmaceutical Company Limited
- AstraZeneca plc
Table Information
| Report Attribute | Details |
|---|---|
| No. of Pages | 250 |
| Published | February 2026 |
| Forecast Period | 2026 - 2030 |
| Estimated Market Value ( USD | $ 6.89 Billion |
| Forecasted Market Value ( USD | $ 10.96 Billion |
| Compound Annual Growth Rate | 12.3% |
| Regions Covered | Global |
| No. of Companies Mentioned | 22 |
